NASDAQ:ZYBT Zhengye Biotechnology Q4 2025 Earnings Results & Report $1.58 +0.10 (+7.03%) As of 03:28 PM Eastern This is a fair market value price provided by Massive. Learn more. Zhengye Biotechnology reported Q4 2025 earnings on April 28, 2026. The company reported EPS of -$0.0750, while revenue was $3.97 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateApril 28, 2026TimeAfter Market Closes Zhengye Biotechnology EPS ResultsActual EPS-$0.0750Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AZhengye Biotechnology Revenue ResultsActual Revenue$3.97 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Zhengye Biotechnology Q4 2025 Earnings FAQ Did Zhengye Biotechnology beat earnings estimates for Q4 2025? Zhengye Biotechnology (NASDAQ:ZYBT) reported earnings of -$0.0750 per share for Q4 2025. The report was announced on Tuesday, April 28, 2026. What was Zhengye Biotechnology's revenue for Q4 2025? Zhengye Biotechnology reported revenue of $3.97 million for Q4 2025. Zhengye Biotechnology Earnings HeadlinesZhengye Biotechnology (NASDAQ:ZYBT) Shares Up 4.5% - Here's WhyOctober 8, 2026 | americanbankingnews.comZhengye Biotechnology Holding Ltd (ZYBT)August 28, 2026 | ru.investing.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.October 14 at 1:00 AM | Investors Alley (Ad)Zhengye Biotechnology Regains Nasdaq Minimum Bid Price ComplianceAugust 6, 2026 | tipranks.comWhy Zhengye Biotechnology Holding (ZYBT) Stock Is Up TodayAugust 5, 2026 | quiverquant.comQZhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | BenzingaJuly 23, 2026 | benzinga.comSee More Zhengye Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zhengye Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zhengye Biotechnology and other key companies, straight to your email. Email Address About Zhengye BiotechnologyZhengye Biotechnology (NASDAQ:ZYBT) is a China-based biotechnology company focused on the research, development, manufacturing and sale of veterinary biological products. Through its operating subsidiaries, the company serves the animal-health market, with products intended to help prevent and control infectious diseases affecting livestock and poultry. The company’s product portfolio primarily consists of animal vaccines and related veterinary biological products. Its offerings are designed for use by animal farms, veterinary institutions and other participants in China’s livestock and poultry industries. Zhengye Biotechnology operates in China and is headquartered in Jilin Province. The company conducts its business through its Chinese operating entities; detailed, reliably verifiable information about its executive leadership and broader international operations is limited.View Zhengye Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
